Investigation on antiviral agents against severe fever with thrombocytopenia syndrome virus (SFTSV)
Project/Area Number |
26460559
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Virology
|
Research Institution | Kagoshima University |
Principal Investigator |
BABA MASANORI 鹿児島大学, 医歯学域医学系, 教授 (70181039)
|
Co-Investigator(Kenkyū-buntansha) |
有馬 直道 鹿児島大学, 医歯学総合研究科, 客員研究員 (30175997)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 重症熱性血小板減少症候群 / SFTSV / 抗ウイルス薬 / アッセイシステム / アモジアキン |
Outline of Final Research Achievements |
SFTS is an emerging tick-borne infectious disease. Its fatality is quite high. However, there are no antiviral agents currently approved for clinical use. We have established a safe and rapid assay system for screening selective inhibitors of SFTSV and tested various compounds in the assay system. When ribavirin and favipiravir were examined for their anti-SFTSV activity, their EC50 values were 40.1 ± 16.3 and 25.0 ± 9.3 μM, respectively. Both compounds have already been reported as selective inhibitors of SFTSV replication in vitro. Furthermore, amodiaquine was found to be effective against SFTSV (EC50 = 19.1 ± 5.1 μM).
|
Report
(4 results)
Research Products
(2 results)